title: MUC1 in hematological malignancies.
abstract: Mucin1 (MUC1) is a transmembrane oncogenic protein that plays a central role in malignant transformation and disease evolution, including cell proliferation, survival, self-renewal, and metastatic invasion. MUC1 has been shown to interact with diverse effectors such as β-catenin, receptor tyrosine kinases, and c-Abl, which are of importance in the pathogenesis of various hematological malignancies. In myeloid leukemia, MUC1 has been shown to have an essential role in leukemia stem-cell function, the induction of reactive oxygen species (ROS), and the promotion of terminal myeloid differentiation. As such, MUC1 is an attractive therapeutic target in hematologic malignancies. Targeting MUC1 has been shown to be an effective approach for inducing cell death in tumor in in vivo and in vitro models. Furthermore, MUC1 inhibition is synergistic with other therapeutic agents in the treatment of hematologic disorders. This review will explore the role of MUC1 in hematological malignancies, and strategies for targeting this oncoprotein.
authors.affiliation: a Beth Israel Deaconess Medical Center , Harvard Medical School , Boston , MA , USA ;
authors.forename: Dina
authors.initials: D
authors.lastname: Stroopinsky
authors.affiliation: b Dana Farber Cancer Institute, Harvard Medical School , Boston , MA , USA.
authors.forename: Donald
authors.initials: D
authors.lastname: Kufe
authors.affiliation: a Beth Israel Deaconess Medical Center , Harvard Medical School , Boston , MA , USA ;
authors.forename: David
authors.initials: D
authors.lastname: Avigan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D015972:Gene Expression Regulation, Neoplastic; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D018396:Mucin-1 / Q000235:genetics* / Q000378:metabolism*; D015513:Oncogene Proteins / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D018396:Mucin-1; D015513:Oncogene Proteins
keywords: AML; MUC1; ROS; multiple myeloma